• Hypertension is a global problem

    The incidence of high blood pressure is increasing worldwide, particularly in Asia.1 Raised blood pressure predicts an increased risk of CVD.2

  • Sustained long-term BP control

    Adalat GITS provides sustained long-term BP control in a wide range of patients, including those with additional cardiovascular risk factors.3-7 Adalat GITS has been demonstrated efficacy in monotherapy4 and combination therapy,8-11 and has a well-established safety profile.12

  • Preferred partner for combination therapy

    Most patients require combination therapy to reach target blood pressure.13,14 Adalat GITS, as a calcium channel blocker, is a preferred combination partner for ACE inhibitors and ARBs (renin-angiotensin targeting drugs), due to its complementary mechanism of action.8-11,15-17

  • Favourable PK/PD profile

    The unique osmotic ‘push-pull’ delivery system of Adalat GITS allows controlled, consistent drug release over 24 hours with once-daily dosing.18-20 Adalat GITS has a superior pharmacokinetic profile compared to generic nifedipine formulations.19-22 In addition, Adalat GITS has a low degree of sympathetic nervous system activation with minimal effects on heart rate while showing similar BP reductions compared to amplodipine.23

Guideline recommendations for CCBs

Dihydropyridine CCBs are a recommended therapeutic option in the ESH/ESC 2013 guideline on hypertension, and are further identified as the only drug class with no compelling contraindication to use.13 Recommendations for CCBs are found in many other national hypertension guidelines, including those for the USA, Canada, China, Korea and Taiwan.24-29



  1. Kearney PM, et al. Lancet 2005;365:217-23.
  2. Arima H, et al. Hypertension 2012;59:1118-23.
  3. Mancia G, et al. J Hypertens 2002;20:545-53.
  4. Brown M, et al. Lancet 2000;356:366-72.
  5. Mancia G, et al. Hypertension 2003;41:431-6.
  6. Bravo EL, et al. Am J Hypertens 1990;3:326S-32S.
  7. Mancia G, et al. Blood Press 2004;13:310-5.
  8. Mancia G, et al. J Hypertens 2011;29:600-9.
  9. Kuschnir E, et al. J Cardiovasc Pharmacol 2004;43:300-5.
  10. Hasebe N, et al. J Hypertens 2005;23:445-53.
  11. Ke Y-N, et al. Cardiovasc Ther 2012;30:326-32.
  12. Adalat Health Care Professional Information.
  13. Mancia G, et al. Eur Heart J. 2013;34(28):2159-219.
  14. Canadian Hypertension Education Programm [Internet]. Available from: http://goo.gl/j8oACH. Accessed 15th February 2018.
  15. Haller H. Int J Clin Pract 2008;62:781–90.
  16. Taddei S, et al. J Cardiovasc Pharmacol 2003;41:579-85.
  17. Toal CB, et al. Can J Cardiol 1999;15:1103-9.
  18. Grundy JS, et al. Clin Pharmacokinet 1996;30:28-51.
  19. Toal CB, et al. Int J Clin Pharmacol Ther 2012;50:202-17.
  20. Meredith PA, et al. J Hypertens 2004;22:1641-8.
  21. Schug BS, et al. Eur J Clin Pharmacol 2002;58:119-25.
  22. Anschutz M, et al. Int J Clin Pharmacol Ther 2010;48:158-70.
  23. Toal CB, et al. Blood Press. 2012;21 Suppl 1:3-10.
  24. James PA, et al. JAMA 2014;311(5):507-520.
  25. Flack JM, et al. Hypertension 2010;56:780-800. Available at: http://goo.gl/o85pwp. Accessed 10 October 2017.
  26. Canadian Hypertension Education Programm [Internet]. Available from: http://goo.gl/j8oACH. Accessed 15th February 2018.
  27. Liu LS, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579-615.
  28. Park JB. Korean Circulation J. 2006;36:405-10. Available from: https://synapse.koreamed.org/Synapse/Data/PDFData/0054KCJ/kcj-36-405.pdf. Accessed 10 October 2017.
  29. Chiang CE, et al. J Formos Med Assoc. 2010;109:740-73. Available from: http://www.jfma-online.com/article/S0929-6646(10)60120-9/pdf. Accessed 10 October 2017.